BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Clinical Outcome
11 results:

  • 1. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
    Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell lymphomas.
    Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
    Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma.
    Martin-Guerrero I; Salaverria I; Burkhardt B; Chassagne-Clement C; Szczepanowski M; Bens S; Klapper W; Zimmermann M; Kabickova E; Bertrand Y; Reiter A; Siebert R; Oschlies I
    Genes Chromosomes Cancer; 2019 Jun; 58(6):365-372. PubMed ID: 30578714
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
    Shinozuka K; Tang H; Jones RB; Li D; Nieto Y
    Biol Blood Marrow Transplant; 2016 May; 22(5):843-9. PubMed ID: 26743341
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Characterization of genetic changes in MCL by interphase FISH on tissue sections.
    Sander B; Wallblom A; Ekroth A; Porwit A; Kimby E
    Leuk Lymphoma; 2007 Jul; 48(7):1344-52. PubMed ID: 17613764
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Bulky lymphadenopathy with poor clinical outcome is associated with atm downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
    Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
    Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Relation between genetic variants of the ataxia telangiectasia-mutated (atm) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
    Meier M; den Boer ML; Hall AG; Irving JA; Passier M; Minto L; van Wering ER; Janka-Schaub GE; Pieters R
    Leukemia; 2005 Nov; 19(11):1887-95. PubMed ID: 16167060
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
    Rubio-Moscardo F; Climent J; Siebert R; Piris MA; Martín-Subero JI; Nieländer I; Garcia-Conde J; Dyer MJ; Terol MJ; Pinkel D; Martinez-Climent JA
    Blood; 2005 Jun; 105(11):4445-54. PubMed ID: 15718413
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Cryptic deletion involving the atm locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders.
    Eclache V; Caulet-Maugendre S; Poirel HA; Djemai M; Robert J; Lejeune F; Raphaël M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):72-6. PubMed ID: 15193446
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
    Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Lysis of autologous tumor cells by large granular lymphocytes in patients with acute leukemia in complete remission: correlation between lytic activity and clinical outcome.
    Ezaki K; Okamoto M; Tsuzuki M; Wakita M; Nomura T; Miyazaki H; Maruyama F; Kojima H; Matsui T; Ino T
    Leuk Res; 1994 May; 18(5):357-63. PubMed ID: 8182926
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.